Literature DB >> 16412064

Identification of Leishmania donovani antigens stimulating cellular immune responses in exposed immune individuals.

P Tripathi1, S Ray, S Sunder, A Dube, S Naik.   

Abstract

Human visceral leishmaniasis (VL), also known as kala azar (KA) in India, is a systemic progressive disease caused by Leishmania donovani. In VL, Th1 responses correlate with recovery from and resistance to disease and resolution of infection results in lifelong immunity against the disease. However, recent data suggest an important role for interleukin (IL)-10 in maintaining the resistant state. We evaluated whole cell extract (WE) and 11 antigenic fractions [F1-F11, molecular weight (MW) range of 139-24.2 kDa] from L. donovani (2001 strain, a fresh field isolate from Bihar), for their ability to induce in vitro T cell proliferation and production of interferon (IFN)-gamma, interleukin (IL)-12, IL-10 and IL-4 by peripheral blood mononuclear cells (PBMCs) of exposed immune individuals (14 patients with history of VL, 10 household endemic contacts) and 20 non-endemic healthy controls. Twenty-one of 24 exposed individuals and no healthy controls showed proliferative response to WE. Whole-extract activated IFN-gamma, IL-12, IL-10 levels were higher in the exposed group than in controls; IL-4 was not detectable in any of the samples. Among 21 responders to WE, frequent proliferative responses were seen to fractions F1-F4 (MW > 64.2 kDa) and none to fractions F5-F11; fractions F1-F11 stimulated comparable levels of IFN-gamma and IL-12 while IL-10 levels were higher in response to F5-F11 compared to F1-F4. These data demonstrate the presence of immunostimulatory antigens in the high MW fractions of whole L. donovani antigen. However, these fractions do not stimulate a Th1 response and produce variable amounts of IFN-gamma and the regulatory cytokine, IL-10. Hence, these high MW immunostimulatory fractions need to be evaluated in greater depth for their possible role as protective antigens.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16412064      PMCID: PMC1809583          DOI: 10.1111/j.1365-2249.2005.03000.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  47 in total

1.  CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity.

Authors:  Yasmine Belkaid; Ciriaco A Piccirillo; Susana Mendez; Ethan M Shevach; David L Sacks
Journal:  Nature       Date:  2002-12-05       Impact factor: 49.962

Review 2.  The immunology of susceptibility and resistance to Leishmania major in mice.

Authors:  David Sacks; Nancy Noben-Trauth
Journal:  Nat Rev Immunol       Date:  2002-11       Impact factor: 53.106

3.  Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani.

Authors:  E Paraguai de Souza; R R Bernardo; M Palatnik; C B Palatnik de Sousa
Journal:  Vaccine       Date:  2001-04-30       Impact factor: 3.641

4.  Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection.

Authors:  M M Gicheru; J O Olobo; C O Anjili; A S Orago; F Modabber; P Scott
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

5.  Identification and characterization of T cell-stimulating antigens from Leishmania by CD4 T cell expression cloning.

Authors:  P Probst; E Stromberg; H W Ghalib; M Mozel; R Badaro; S G Reed; J R Webb
Journal:  J Immunol       Date:  2001-01-01       Impact factor: 5.422

6.  Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease.

Authors:  A Campos-Neto; R Porrozzi; K Greeson; R N Coler; J R Webb; Y A Seiky; S G Reed; G Grimaldi
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

7.  The Leishmania mexicana cysteine protease, CPB2.8, induces potent Th2 responses.

Authors:  Kevin G J Pollock; Katherine S McNeil; Jeremy C Mottram; Russell E Lyons; James M Brewer; Phillip Scott; Graham H Coombs; James Alexander
Journal:  J Immunol       Date:  2003-02-15       Impact factor: 5.422

8.  Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant.

Authors:  Yasir A W Skeiky; Rhea N Coler; Mark Brannon; Erika Stromberg; Kay Greeson; R Thomas Crane; John R Webb; Antonio Campos-Neto; Steven G Reed
Journal:  Vaccine       Date:  2002-09-10       Impact factor: 3.641

Review 9.  Regulatory role of T cells producing both interferon gamma and interleukin 10 in persistent infection.

Authors:  G Trinchieri
Journal:  J Exp Med       Date:  2001-11-19       Impact factor: 14.307

10.  The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure.

Authors:  Y Belkaid; K F Hoffmann; S Mendez; S Kamhawi; M C Udey; T A Wynn; D L Sacks
Journal:  J Exp Med       Date:  2001-11-19       Impact factor: 14.307

View more
  8 in total

1.  Anti-leishmanial and toxicity activities of some selected Iranian medicinal plants.

Authors:  Hamidreza Kheiri Manjili; Hamidreza Jafari; Ali Ramazani; Noushin Davoudi
Journal:  Parasitol Res       Date:  2012-08-09       Impact factor: 2.289

2.  Immunoprotective responses of T helper type 1 stimulatory protein-S-adenosyl-L-homocysteine hydrolase against experimental visceral leishmaniasis.

Authors:  P Khare; A K Jaiswal; C D P Tripathi; S Sundar; A Dube
Journal:  Clin Exp Immunol       Date:  2016-04-27       Impact factor: 4.330

Review 3.  Potential biomarkers of immune protection in human leishmaniasis.

Authors:  Mahmoud Nateghi Rostami; Ali Khamesipour
Journal:  Med Microbiol Immunol       Date:  2021-05-02       Impact factor: 3.402

4.  Immunity to visceral leishmaniasis using genetically defined live-attenuated parasites.

Authors:  Angamuthu Selvapandiyan; Ranadhir Dey; Sreenivas Gannavaram; Ines Lakhal-Naouar; Robert Duncan; Poonam Salotra; Hira L Nakhasi
Journal:  J Trop Med       Date:  2011-09-06

5.  Leishmania donovani: immunostimulatory cellular responses of membrane and soluble protein fractions of splenic amastigotes in cured patient and hamsters.

Authors:  Shraddha Kumari; Pragya Misra; Rati Tandon; Mukesh Samant; Shyam Sundar; Anuradha Dube
Journal:  PLoS One       Date:  2012-01-26       Impact factor: 3.240

6.  Characterization of glycolytic enzymes--rAldolase and rEnolase of Leishmania donovani, identified as Th1 stimulatory proteins, for their immunogenicity and immunoprophylactic efficacies against experimental visceral leishmaniasis.

Authors:  Reema Gupta; Vikash Kumar; Pramod Kumar Kushawaha; Chandradev Pati Tripathi; Sumit Joshi; Amogh Anant Sahasrabuddhe; Kalyan Mitra; Shyam Sundar; Mohammad Imran Siddiqi; Anuradha Dube
Journal:  PLoS One       Date:  2014-01-24       Impact factor: 3.240

7.  Comparative Analysis of Cellular Immune Responses in Treated Leishmania Patients and Hamsters against Recombinant Th1 Stimulatory Proteins of Leishmania donovani.

Authors:  Sumit Joshi; Narendra K Yadav; Keerti Rawat; Chandra Dev P Tripathi; Anil K Jaiswal; Prashant Khare; Rati Tandon; Rajendra K Baharia; Sanchita Das; Reema Gupta; Pramod K Kushawaha; Shyam Sundar; Amogh A Sahasrabuddhe; Anuradha Dube
Journal:  Front Microbiol       Date:  2016-03-22       Impact factor: 5.640

8.  Gene deleted live attenuated Leishmania vaccine candidates against visceral leishmaniasis elicit pro-inflammatory cytokines response in human PBMCs.

Authors:  Kumar Avishek; Himanshu Kaushal; Sreenivas Gannavaram; Ranadhir Dey; Angamuthu Selvapandiyan; V Ramesh; Narender Singh Negi; Uma S Dubey; Hira L Nakhasi; Poonam Salotra
Journal:  Sci Rep       Date:  2016-09-14       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.